CYP19A1 and breast fibrocystic disease: Although antihormonal therapy (e.g., tamoxifen and aromatase inhibitor) seems to reduce the incidence of clinically detected benign breast disease and could in part explain this finding, we found that a similar percentage of other benign lesions was present in the two groups of patients [28].